Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 504 institutions reported holding it in 13F filings for Q2 2026, worth $9.75B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:15 AM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2026: $724.2M (160.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Nov 12, 2026 | Nov 25, 2025 | Nov 26, 2024 | Nov 29, 2023 | Nov 28, 2022 |
| Revenue | $450.8M | $829.4M | $3.55M | $240.7M | $243.2M |
| Operating expenses | $1.16B | $731.1M | $604.6M | $445.7M | $421.7M |
| Research and development | $739.1M | $607.2M | $505.9M | $353.2M | $297.3M |
| Selling, general and administrative | $202.0M | $123.9M | $98.8M | $92.5M | $124.4M |
| Operating income | -$707.2M | $98.3M | -$601.1M | -$205.0M | -$178.5M |
| Interest expense | – | – | – | $18.3M | – |
| Income tax | -$6.78M | $21.4M | -$2.77M | $2.78M | $3.79M |
| Net income | -$724.2M | -$1.63M | -$599.5M | -$205.3M | -$176.1M |
| EPS, basic | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 |
| EPS, diluted | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 |
| Weighted shares, basic | 141.6M | 133.8M | 119.8M | 106.8M | 105.4M |
| Weighted shares, diluted | 141.6M | 133.8M | 119.8M | 106.8M | 105.4M |
| Margins and growth | |||||
| Operating margin | -156.9% | 11.9% | -16927.1% | -85.2% | -73.4% |
| Net margin | -160.6% | -0.2% | -16882.4% | -85.3% | -72.4% |
| Revenue growth, year over year | −45.6% | +23,258.2% | −98.5% | −1.0% | +75.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Nov 12, 2026 | Nov 25, 2025 | Nov 26, 2024 | Nov 29, 2023 | Nov 28, 2022 |
| Short-term investments | – | – | – | – | $0 |
| Accounts receivable | $9.93M | $6.82M | – | $0 | $1.41M |
| Inventory | $9.07M | – | – | – | – |
| Total current assets | $1.29B | $950.6M | $695.5M | $419.5M | $405.3M |
| Property, plant and equipment | $371.3M | $382.5M | $386.0M | $290.3M | $110.3M |
| Intangible assets | $5.16M | $6.86M | $8.56M | $10.3M | $12.0M |
| Total assets | $1.74B | $1.39B | $1.14B | $765.6M | $691.9M |
| Accounts payable | $30.1M | $17.7M | $11.4M | $35.9M | $2.87M |
| Total current liabilities | $311.3M | $195.5M | $103.2M | $105.5M | $138.8M |
| Shareholders' equity | $50.5M | $503.4M | $191.1M | $287.2M | $418.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Nov 12, 2026 | Nov 25, 2025 | Nov 26, 2024 | Nov 29, 2023 | Nov 28, 2022 |
| Operating cash flow | -$271.9M | $179.6M | -$462.9M | -$153.9M | -$136.1M |
| Capital expenditures | $12.0M | $22.7M | $141.5M | $176.7M | $52.8M |
| Free cash flow | -$283.9M | $156.9M | -$604.3M | -$330.6M | -$188.9M |
| Depreciation and amortization | $24.7M | $22.2M | $16.9M | $10.7M | $8.70M |
| Stock-based compensation | $68.1M | $63.4M | $74.0M | $78.1M | $120.9M |
| Investing cash flow | -$670.5M | -$129.3M | -$420.1M | -$96.2M | -$5.42M |
| Financing cash flow | $776.8M | $74.0M | $870.5M | $253.1M | $65.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15.1% | 7.6% | 2083.0% | 32.5% | 49.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 141.4M | +4.1% | SEC |
| Jul 30, 2026 | 141.3M | +2.2% | SEC |
| May 1, 2026 | 140.9M | +2.0% | SEC |
| Jan 30, 2026 | 140.0M | +11.1% | SEC |
| Nov 19, 2025 | 135.8M | +9.1% | SEC |
| Aug 1, 2025 | 138.3M | +11.2% | SEC |
| May 1, 2025 | 138.1M | +11.2% | SEC |
| Feb 3, 2025 | 126.1M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.